Regulatory Pathway for Registration of Biosimilars in Russia
Biological products or biopharmaceuticals are medicinal products derived from living organism systems and manufactured by using modern biotechnology that differ widely from the conventional synthetic drugs. According to some estimates, Russia is poised to be among the top five global pharmaceutical Markets in terms of value in the next couple of years. Due to the impetus shown by the government regarding the evolution of the Russian regulatory framework for pharmaceutical products, this and other market trends suggest that Russia will soon become a powerhouse destination for pharmaceutical manufacturers and contract research organizations.
Russian law allows the registration of biological drugs defined as medicinal products containing a biological active substance. A biological active substance is a substance that is produced by or extracted from a biological source and requires physical, chemical and biological testing, characterization of its quality, along with its production process and control. It does not define a biosimilar, nor it provides a regulatory framework for the biosimilar approval; this implies that a full clinical developmental program, similar to the innovator biological product, must be completed even for a biosimilar. An applicant must submit a registration dossier to the Ministry of Health (MoH), the regulatory body for drugs evaluation, with its affiliation Federal State Budgetary Institution - Scientific Centre for Expert Evaluation of Medicinal Products (FSBI-SCEMP). The complete dossier in Russian must be submitted to the MoH, and should include administrative documents, description of pharmaceutical properties and data about the manufacturing process, quality control, preclinical studies (pharmacological and toxicological) and clinical studies regarding the biological drug. Russia follows the European Guidelines for biosimilars for data requirements for the registration of a biological drug. Today, Russia stands on the verge of becoming a major force in the global pharmaceutical market. The exact contours of its future are as yet undefined; challenges and opportunities co-exist in equal measure. The Russia of today is not the Russia of yesteryears, and tomorrow’s Russia will take yet a different face again.
The objective of this manuscript is to explore the Regulatory pathway for registration of Biosimilars in Russia.
2. Russian Market growth. Https://www.export.gov/article?Id=Russia-Pharmaceuticals
3. New Russian law tightens the procedure for putting medicines on the market and complicates ending distribution agreements. Https://www.lexology.com/library/detail.aspx?G=41c32c6e-8585-42cf-bdb3-d7b588573104
4. Pharma strategy 2030. Https://www.uawire.org/russian-pharmaceutical-companies-told-to-prepare-for-war
5. Lets Have An Introduction To What Is Russia!. Https://ribttes.com/what-is-russia/
6. Russia: where East meets West. Https://www.akdmc.com/destinations/europe/russia/
7. Conducting drug clinical trials in Russia: today and what lies ahead: https://pink.pharmamedtechbi.com/PS118035/Conducting-drug-clinical-trials-in-Russia-today-and-what-lies-ahead
8. Regulations in Russia; http://www.epmmagazine.com/blogs/regulatory-affairs-column/russia-and-cis-navigating-a-fast-changing-regulatory-lands/
9. Amendments to the Federal Law “On Circulation of Pharmaceuticals”:
10. Rajesh Kumar, Sandra Sigala, Renato Bertini Malgarini, Giuseppe Pimpinella, Luca Pani, Sergio Pecorelli et al. Biosimilars: Regulatory Status and Implications across the World; J Pharmacovigilance 2015, S3.
11. Russian regulatory authority. Http://www.roszdravnadzor.ru/en
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).